384 related articles for article (PubMed ID: 28574690)
21. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
[TBL] [Abstract][Full Text] [Related]
22. β-Carboline tethered cinnamoyl 2-aminobenzamides as class I selective HDAC inhibitors: Design, synthesis, biological activities and modelling studies.
Namballa HK; Anchi P; Lakshmi Manasa K; Soni JP; Godugu C; Shankaraiah N; Kamal A
Bioorg Chem; 2021 Dec; 117():105461. PubMed ID: 34753060
[TBL] [Abstract][Full Text] [Related]
23. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
[TBL] [Abstract][Full Text] [Related]
24. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
Ojha R; Huang HL; HuangFu WC; Wu YW; Nepali K; Lai MJ; Su CJ; Sung TY; Chen YL; Pan SL; Liou JP
Eur J Med Chem; 2018 Apr; 150():667-677. PubMed ID: 29567459
[TBL] [Abstract][Full Text] [Related]
25. Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-based Histone Deacetylase Inhibitors.
Abdelkarim H; Neelarapu R; Madriaga A; Vaidya AS; Kastrati I; Karumudi B; Wang YT; Taha TY; Thatcher GRJ; Frasor J; Petukhov PA
ChemMedChem; 2017 Dec; 12(24):2030-2043. PubMed ID: 29080240
[TBL] [Abstract][Full Text] [Related]
26. Preferential HDAC6 inhibitors derived from HPOB exhibit synergistic antileukemia activity in combination with decitabine.
Tretbar M; Schliehe-Diecks J; von Bredow L; Tan K; Roatsch M; Tu JW; Kemkes M; Sönnichsen M; Schöler A; Borkhardt A; Bhatia S; Hansen FK
Eur J Med Chem; 2024 Jun; 272():116447. PubMed ID: 38714044
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L
Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.
Sodji QH; Patil V; Kornacki JR; Mrksich M; Oyelere AK
J Med Chem; 2013 Dec; 56(24):9969-81. PubMed ID: 24304348
[TBL] [Abstract][Full Text] [Related]
29. Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.
Aboeldahab AMA; Beshr EAM; Shoman ME; Rabea SM; Aly OM
Eur J Med Chem; 2018 Feb; 146():79-92. PubMed ID: 29396364
[TBL] [Abstract][Full Text] [Related]
30. Design, Synthesis and Biological Evaluation of Novel Benzoylimidazole Derivatives as Raf and Histone Deacetylases Dual Inhibitors.
Chen X; Gong G; Chen X; Song R; Duan M; Qiao R; Jiao Y; Qi J; Chen Y; Zhu Y
Chem Pharm Bull (Tokyo); 2019; 67(10):1116-1122. PubMed ID: 31582631
[TBL] [Abstract][Full Text] [Related]
31. Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity.
Pidugu VR; Yarla NS; Pedada SR; Kalle AM; Satya AK
Bioorg Med Chem; 2016 Nov; 24(21):5611-5617. PubMed ID: 27665180
[TBL] [Abstract][Full Text] [Related]
32. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, and preliminary bioactivity evaluation of N-benzylpyrimidin-2-amine derivatives as novel histone deacetylase inhibitor.
Zhou Y; Dun Y; Fu H; Wang L; Pan X; Yang X; Fang H
Chem Biol Drug Des; 2017 Nov; 90(5):936-942. PubMed ID: 28489276
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
Tashima T; Murata H; Kodama H
Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
[TBL] [Abstract][Full Text] [Related]
35. Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
El-Awady R; Saleh E; Hamoudi R; Ramadan WS; Mazitschek R; Nael MA; Elokely KM; Abou-Gharbia M; Childers WE; Srinivasulu V; Aloum L; Menon V; Al-Tel TH
Bioorg Med Chem; 2021 Jul; 42():116251. PubMed ID: 34116381
[TBL] [Abstract][Full Text] [Related]
36. Quinolone-based HDAC inhibitors.
Balasubramanian G; Kilambi N; Rathinasamy S; Rajendran P; Narayanan S; Rajagopal S
J Enzyme Inhib Med Chem; 2014 Aug; 29(4):555-62. PubMed ID: 25019596
[TBL] [Abstract][Full Text] [Related]
37. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of β-boswellic acid based HDAC inhibitors as inducers of cancer cell death.
Sharma S; Ahmad M; Bhat JA; Kumar A; Kumar M; Zargar MA; Hamid A; Shah BA
Bioorg Med Chem Lett; 2014 Oct; 24(19):4729-4734. PubMed ID: 25176189
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors.
Routholla G; Pulya S; Patel T; Abdul Amin S; Adhikari N; Biswas S; Jha T; Ghosh B
Bioorg Chem; 2021 Sep; 114():105050. PubMed ID: 34120025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
